Biomotiv
 |
|
| Industry | Biotechnology |
|---|---|
| Founded | Cleveland, Ohio, 2012 |
|
Key people
|
Baiju Shah, CEO |
| Subsidiaries | Orca Pharmaceuticals Dual Therapeutics Kodosil Bio OptiKira |
| Website | www |
BioMotiv is an accelerator company associated with The Harrington Project, a national initiative centered at University Hospitals of Cleveland. The company is designed to accelerate breakthrough discoveries into medicines by advancing a portfolio of novel therapeutics in all disease areas and types of therapeutics — small molecules, antibodies, proteins, cell therapies, and nucleotides – from the discovery to pre-clinical stages of development and will also consider drug re-purposing opportunities. Opportunities are sourced primarily through relationships with research institutions and disease foundations.
In response to recent decline in the number of traditional biotechnology venture capital firms, BioMotiv utilizes an asset-centric model to in-license, fund, and manage technologies in-house. Their goal is to address the “valley of death" between research, discovery, and early clinical-stage drug development. Projects are advanced by the management team through clinical proof-of-concept and then out-licensed via strategic alliances with pharmaceutical companies.
The company has raised over $135 million to date, with a goal of raising $150 million in total. Major investors include The Harrington Family, University Hospitals of Cleveland, Nationwide Mutual Insurance Company,Takeda Pharmaceutical Company,Biogen,Arix Bioscience and Charles River Laboratories.
BioMotiv is managed by an executive team, including
The company attracted Baiju R. Shah, former CEO of BioEnterprise, a non-profit aimed at boosting Cleveland’s healthcare economy, to lead its efforts. Prior to founding BioEnterprise, Baiju Shah worked at McKinsey & Company. David C. U’Prichard, PhD is Chairman of the Advisory Board; he has served on a number of biotechnology boards, as a venture partner at several funds, and was Chairman of Research and Development at SmithKline Beecham. Ted Torphy, PhD is the Chief Scientific Officer; he is an advisor to the Cystic Fibrosis Foundation and was previously Global Head of External Innovation at Johnson & Johnson.
...
Wikipedia